Author + information
- Received April 6, 2015
- Revision received June 4, 2015
- Accepted June 4, 2015
- Published online November 1, 2015.
- Maros Ferencik, MD, PhD∗,†,‡∗ (, )
- Ting Liu, MD†,‡,§,
- Thomas Mayrhofer, PhD†,‡,
- Stefan B. Puchner, MD†,‡,‖,
- Michael T. Lu, MD†,‡,
- Pal Maurovich-Horvat, MD, MPH¶,
- J. Hector Pope, MD#,
- Quynh A. Truong, MD, MPH†,‡∗∗,
- James E. Udelson, MD††,
- W. Frank Peacock, MD‡‡,
- Charles S. White, MD§§,
- Pamela K. Woodard, MD‖‖,
- Jerome L. Fleg, MD¶¶,
- John T. Nagurney, MD, MPH##,
- James L. Januzzi, MD∗∗∗ and
- Udo Hoffmann, MD, MPH†,‡∗∗∗
- ∗Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon
- †Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- ‡Cardiac MR PET CT Program, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- §Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, China
- ‖Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria
- ¶TA-SE Lendület Cardiovascular Imaging Research Group, Heart and Vascular Centre, Semmelweis University, Budapest, Hungary
- #Department of Emergency Medicine, Baystate Medical Center, Springfield, Massachusetts
- ∗∗Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medical College, New York, New York
- ††Division of Cardiology and the Cardio-Vascular Center, Tufts Medical Center, Boston, Massachusetts
- ‡‡Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas
- §§University of Maryland School of Medicine, Baltimore, Maryland
- ‖‖Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
- ¶¶Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland
- ##Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- ∗∗∗Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- ↵∗Reprint requests and correspondence:
Dr. Maros Ferencik, Knight Cardiovascular Institute, Oregon Health and Science University, 3180 Sam Jackson Park Road, Mail Code UHN62, Portland, Oregon 97239.
Objectives This study compared diagnostic accuracy of conventional troponin/traditional coronary artery disease (CAD) assessment and highly sensitive troponin (hsTn) I/advanced CAD assessment for acute coronary syndrome (ACS) during the index hospitalization.
Background hsTnI and advanced assessment of CAD using coronary computed tomography angiography (CTA) are promising candidates to improve the accuracy of emergency department evaluation of patients with suspected ACS.
Methods We performed an observational cohort study in patients with suspected ACS enrolled in the ROMICAT II (Rule Out Myocardial Infarction/Ischemia using Computer Assisted Tomography) trial and randomized to coronary CTA who also had hsTnI measurement at the time of the emergency department presentation. We assessed coronary CTA for traditional (no CAD, nonobstructive CAD, ≥50% stenosis) and advanced features of CAD (≥50% stenosis, high-risk plaque features: positive remodeling, low <30-Hounsfield units plaque, napkin-ring sign, spotty calcium).
Results Of 160 patients (mean age: 53 ± 8 years, 40% women) 10.6% were diagnosed with ACS. The ACS rate in patients with hsTnI below the limit of detection (n = 9, 5.6%), intermediate (n = 139, 86.9%), and above the 99th percentile (n = 12, 7.5%) was 0%, 8.6%, and 58.3%, respectively. Absence of ≥50% stenosis and high-risk plaque ruled out ACS in patients with intermediate hsTnI (n = 87, 54.4%; ACS rate 0%), whereas patients with both ≥50% stenosis and high-risk plaque were at high risk (n = 13, 8.1%; ACS rate 69.2%) and patients with either ≥50% stenosis or high-risk plaque were at intermediate risk for ACS (n = 39, 24.4%; ACS rate 7.7%). hsTnI/advanced coronary CTA assessment significantly improved the diagnostic accuracy for ACS as compared to conventional troponin/traditional coronary CTA (area under the curve 0.84, 95% confidence interval [CI]: 0.80 to .88 vs. 0.74, 95% CI: 0.70 to 0.78; p < 0.001).
Conclusions hsTnI at the time of presentation followed by early advanced coronary CTA assessment improves the risk stratification and diagnostic accuracy for ACS as compared to conventional troponin and traditional coronary CTA assessment. (Multicenter Study to Rule Out Myocardial Infarction/Ischemia by Cardiac Computed Tomography [ROMICAT-II]; NCT01084239)
- acute coronary syndrome
- coronary computed tomography angiography
- coronary plaque
- emergency department
- highly sensitive troponin
- risk stratification
Highly sensitive troponin (hsTn) assays and coronary computed tomography angiography (CTA) are promising candidates to improve diagnostic accuracy in patients undergoing evaluation for suspected acute coronary syndrome (ACS) in the emergency department (ED) (1–7). Multiple studies have shown that hsTn assays have increased sensitivity for the detection of ACS and decreased time to assay positivity compared to conventional troponin (1–4). These assay characteristics suggest a potential for faster and more efficient evaluation of patients presenting to the ED with symptoms suggestive of ACS. Several recent studies suggested that even a single very low measurement of hsTn at the time of ED presentation can rule out myocardial infarction (MI) safely (8–10). Further, increasing levels of hsTn are associated with coronary artery disease (CAD) and myocardial perfusion defects, and have prognostic value beyond the acute care episode (11,12).
Three large randomized trials have shown that coronary CTA as compared to standard of care, including serial conventional troponin and functional testing to provoke myocardial ischemia, decreased the time to diagnosis and allowed for earlier discharge from the ED (5–7). Recent data suggest that detection of high-risk coronary plaque features (defined as positive remodeling, low <30 Hounsfield units [HU] plaque, napkin-ring sign, or spotty calcium) is independent and incremental to significant coronary stenosis for diagnosis of ACS (13). The exclusion of high-risk plaque may help to decrease downstream testing (e.g., additional stress testing and invasive coronary angiography). The increase in downstream testing was observed in studies using the traditional assessment of coronary CTA for stenosis (14–16).
Hence, there are expectations that a combination of advanced coronary CTA with hsTn may increase accuracy in the management of patients presenting to the ED with suspected ACS. We designed an observational cohort study nested in the ROMICAT II (Rule Out Myocardial Infarction/Ischemia using Computer Assisted Tomography) trial. We determined whether combined assessment of hsTnI and advanced coronary CTA for high-risk plaque improves accuracy of ACS risk classification as compared to conventional troponins and traditional coronary CTA assessment for stenosis.
The ROMICAT II trial randomized patients presenting to the ED with suggestive ACS but without ischemic electrocardiographic changes and with negative conventional troponins (see Online Table 1 for the conventional troponin assays used in the study) (7). This ancillary study was designed as a nested observational cohort study in patients who were randomized to coronary CTA and consented to blood sampling for hsTnI at the time of ED presentation (Figure 1). All study participants provided written consent for participation in ROMICAT II. The local institutional review boards approved the study. A detailed description of the patient population, including the inclusion and exclusion criteria, was reported previously (7).
Blood samples and hsTnI testing
Blood was collected into tubes containing ethylenediaminetetraacetic acid at baseline and immediately processed and frozen at –80° centigrade until the completion of the study. The samples were obtained at the time of presentation. A second sample was obtained at 90 to 115 min in 140 patients and a third sample was obtained at 210 to 300 min in 105 patients. The blood was then analyzed in a blinded fashion using a pre-clinical highly sensitive method for detecting troponin I (hsVista, Siemens Diagnostics, Newark, Delaware) (1). The limit of detection and 99th percentile values for hsTnI were 0.5 pg/ml and 49 pg/ml, respectively (17). We categorized patients into 3 groups: below the limit of detection (LOD) for the assay (below LOD group), between the LOD and the 99th percentile (intermediate group), and above the 99th percentile (>99th percentile group).
Coronary CTA analysis
Coronary CTA images were acquired using 64-row or newer scanner generations using either retrospectively electrocardiogram-gated or prospectively electrocardiogram-triggered protocols (7). Three readers with at least 5 years of experience in coronary CTA and level III training performed the analysis on a dedicated cardiac workstation (TeraRecon, Foster City, California). The coronary CTA analysis was performed on a per coronary segment basis using the model of the Society of Cardiovascular Computed Tomography (18).
The traditional assessment of coronary CTA was performed in all evaluable coronary segments. Each segment was assessed for the presence of coronary stenosis and plaque. The severity of stenosis was categorized as: 0% = no stenosis, 1% to 49% = nonobstructive CAD, ≥50% = significant CAD.
The advanced assessment for high-risk coronary plaque was performed in all coronary segments with plaque. High-risk plaque was defined as the presence of at least one of the following features: positive remodeling (remodeling index >1.1), presence of plaque with low computed tomographic attenuation of <30 HU plaque, napkin-ring sign, and spotty calcium (Figure 2) (13).
Definition and adjudication of ACS
The primary outcome was ACS during the index hospitalization. ACS was defined as acute MI or unstable angina pectoris according to the American College of Cardiology/American Heart Association Guidelines (19). This endpoint was pre-defined and adjudicated by an external, independent clinical endpoints committee (Online Appendix) (7). The measurements of conventional cardiac troponin at each site were available for adjudication (Online Table 1 summarizes cutoff values for each site). The results of hsTnI and advanced coronary CTA analysis were blinded to the investigators performing the adjudication.
All statistical analyses were performed using Stata 13.1 (StataCorp LP, College Station, Texas). Continuous data are presented as mean ± SD or median (interquartile range), and categorical variables are presented as numbers and percentages. Comparisons between groups were performed with the use of an independent sample Student t test, Wilcoxon rank-sum, or analysis of variance for continuous variables, and the Fisher exact test for categorical variables. For sensitivity, specificity, and positive and negative predictive values, 95% confidence intervals (CIs) were calculated using exact binomial confidence intervals. For the traditional coronary CTA assessment, the test was considered positive if there was any ≥50% stenosis or plaque. For the combined hsTnI and advanced coronary CTA assessment, the test was considered positive if at least 1 of the 3 factors was present: hsTnI result was above the 99th percentile at the time of presentation, ≥50% stenosis or high-risk plaque present on coronary CTA. Areas under the receiver operating characteristics curve (AUC) were compared using the DeLong algorithm (20). The net reclassification index was calculated using the method described by Pencina et al. (21). For all analyses, a 2-tailed p value <0.05 was required to reject the null hypothesis.
Of 501 patients randomized to coronary CTA in the ROMICAT II trial, 472 underwent coronary CTA and had diagnostic image quality. Of those, 160 agreed to participate in blood collection and were included in the nested observational cohort study (Figure 1). The baseline characteristics of the study population are summarized in Table 1. The mean age was 52.7 ± 7.6 years. ACS during the index hospitalization was diagnosed in 19 (10.6%) patients (MI, n = 2; unstable angina pectoris, n = 17). There were no significant differences in baseline demographics, risk factors, and outcomes between patients who agreed to blood collection and the overall cohort of patients randomized to coronary CTA in the ROMICAT II trial (Online Table 2).
Conventional troponin and traditional coronary CTA and ACS
By the ROMICAT II protocol, conventional troponin at the time of presentation to the ED was normal. Based on traditional coronary CTA assessment, 42.5% of patients (n = 68 of 160) had no CAD, 43.8% (n = 70 of 160) had nonobstructive CAD, and 13.8% (n = 22 of 160) had significant CAD (Table 2). Reflecting clinical practice, patients with normal conventional troponin at the time of presentation and no CAD on coronary CTA were stratified as low risk (ACS rate: 0%) and patients who had ≥50% stenosis on coronary CTA were stratified as high risk for ACS (ACS rate: 72.7%). However, nearly one-half of the patients remained at intermediate risk having nonobstructive CAD (ACS rate: 4.3%) (Figure 3).
Association of hsTnI and ACS
In contrast to conventional troponins, hsTnI permitted immediate-risk stratification at the time of ED presentation. Overall, 9 patients (5.6%) had hsTnI below the LOD and 12 (7.5%) had hsTnI above the 99th percentile. The majority of patients had intermediate hsTnI levels (n = 139, 86.9%) (Table 1). The prevalence of ACS was 0% (n = 0 of 9) when hsTnI was below the LOD, 8.6% (n = 12 of 139) in the intermediate hsTnI group and 58.3% (n = 7 of 12) in patients with hsTnI above the 99th percentile. All events in the intermediate group were adjudicated as unstable angina pectoris. Hence, using hsTnI, ACS could be ruled out safely in a small group of patients, obviating the need for subsequent coronary CTA.
The addition of the second and third hsTnI level check did not allow for improvement of risk stratification (data not shown).
Association of high-risk plaque and ACS
At least 1 high-risk plaque feature was present in all patients with ACS. Conversely, only 30.7% of patients without ACS had high-risk plaque. The prevalence of ACS in the coronary CTA strata of no high-risk plaque and no ≥50% stenosis, either high-risk plaque or ≥50% stenosis, and both high-risk plaque and ≥50% stenosis was 0.0%, 7.7%, and 69.2%, respectively. Among patients with hsTnI above the 99th percentile, 66.7% of patients had ≥50% stenosis and 88.3% of patients had high-risk plaque.
Association of CAD and high-risk plaque with hsTnI
Association between the hsTnI strata and presence, extent, and composition of CAD are shown in Table 2. Significant associations were observed for all high-risk plaque features and for significant CAD (≥50% stenosis) (p < 0.01 for each parameter), but not for nonobstructive CAD, indicating that further characterization of nonobstructive CAD for high-risk plaque features is meaningful. None of the patients with hsTnI below the LOD had ≥50% stenosis or high-risk plaque on coronary CTA, whereas 33.3% of patients had nonobstructive CAD.
CAD characteristics and hsTnI levels in patients with intermediated hsTnI
In a subanalysis, we compared CAD characteristics and hsTnI levels in patients with intermediated levels of hsTn (Table 3). Patients with ACS had higher prevalence of ≥50% stenosis and high-risk plaque. The levels of hsTnI were not different between those with and without ACS.
Comparison of the diagnostic accuracy of conventional troponin and traditional coronary CTA versus hsTnI and advanced coronary CTA
A first hsTnI at the time of presentation followed by early coronary CTA with advanced assessment for high-risk plaque improved the accuracy of risk stratification as compared to conventional troponin level and traditional CTA assessment (Figure 4).
Based on the first hsTnI, coronary CTA would not be needed in 13.1% of patients (n = 21): 9 patients (5.6%) with hsTnI below the LOD (ACS rate: 0%) and 12 patients (7.5%) with hsTnI above the 99th percentile (ACS rate: 58.3%). In the remaining 139 patients with intermediate hsTnI, the absence of both high-risk plaque and ≥50% stenosis on coronary CTA excluded ACS in 87 patients (no CAD in 60 patients, nonobstructive CAD in 27 patients). Among the remaining 52 patients, those with either high-risk plaque or ≥50% stenosis represented an intermediate-risk group (n = 39; ACS rate: 7.7%), and those who had both high-risk plaque and ≥50% stenosis (n = 13; ACS rate: 69.2%) represented a high-risk group. Hence, coronary CTA allowed for reclassification of the majority (72%, n = 100 of 139) of patients in the intermediate hsTnI group for ACS risk (Table 4). In 19 patients with ACS, 9 patients were upgraded to high risk for ACS, and no patient was downgraded to low risk for ACS when using advanced coronary CTA results for reclassification. The net gain in reclassification proportion for patients with ACS was 0.47 (95% confidence interval [CI]: 0.16 to 0.78; p = 0.003). The net gain in reclassification proportion for subjects who did not have ACS was 0.59 (95% CI: 0.46 to 0.72; p < 0.001); 87 of 141 patients were reclassified downward and 4 of 141 were reclassified upward. The net reclassification index was thus calculated at 1.06 (95% CI: 0.73 to 1.40; p < 0.001).
The strategy of combined hsTnI and coronary CTA with assessment for high-risk plaque as compared to conventional troponin combined with traditional coronary CTA increased the number of patients in whom ACS could be ruled out from 68 (42.5%) to 96 (60.0%) and the number of patients at high risk for ACS from 22 (13.8%) to 25 (15.7%), whereas the group at intermediate risk decreased from 70 (43.8%) to 39 (24.4%) patients. Overall, the additional information provided by hsTnI and high-risk plaque increased the number of patients categorized into low- or high-risk categories from 82 (51.3%) to 121 (75.6%).
The sensitivity and negative predictive value of combined hsTnI and advanced coronary CTA assessment for ACS were maintained at 100% (similar to conventional troponin and traditional coronary CTA assessment) whereas the specificity improved from 48.2% to 68.1% (Table 5). The combined assessment of hsTnI and advanced coronary CTA for high-risk plaque (AUC: 0.84, 95% CI: 0.80 to 0.88) significantly improved the diagnostic performance for ACS as compared to traditional coronary CTA (AUC: 0.74, 95% CI: 0.70 to 0.78; p < 0.001).
We showed that hsTnI at the time of the ED presentation followed by early coronary CTA with assessment for stenosis and high-risk plaque improved the diagnostic accuracy for ACS in patients with suspected ACS as compared to conventional troponin and traditional coronary CTA assessment. This was based on: 1) the ability of the first hsTnI at the time of presentation to stratify 13.1% into high- or low-risk ACS groups; 2) the reclassification of 71.9% of those with intermediate hsTnI by using additional information from the coronary CTA assessment, thereby decreasing the fraction of patients remaining at intermediate risk for ACS from 43.8% to 24.4%; and 3) the improvement in specificity for ACS in those with intermediate hsTnI levels through assessment of high-risk plaque (from 48.2% to 68.1%) while sensitivity and negative predictive value for ACS were maintained at 100%. Overall, hsTnI at the time of ED presentation followed by early coronary CTA with assessment for stenosis and high-risk plaque significantly improved discriminatory ability for ACS (AUC: 0.74 to 0.84; p < 0.001).
hsTn assays in the assessment of patients with acute chest pain
hsTn assays increase the sensitivity for the detection of smaller amounts of myocardial injury and also decrease the time to assay positivity (1–4). There is growing evidence that hsTn below the LOD measured at the time of presentation has a negative predictive value of >99% for MI, suggesting that it could serve as an early triage tool (1–4,8–10). The triage effectiveness of hsTn using the LOD threshold can be affected by the prevalence of hsTn below the LOD in a population. Prior studies suggest that between 10% and 15% of patients with suspected ACS have hsTnI below the LOD (1–4,10). We found a slightly lower fraction of 6%, which likely represents the extremely high analytical sensitivity of this pre-commercial hsTnI method. None of the patients with hsTnI below the LOD had MI or unstable angina pectoris suggesting that these patients do not need to undergo coronary CTA and a direct discharge from the ED can be considered. Although among a small number of subjects, the importance of this finding cannot be underestimated. Further improvement in efficiency of ACS diagnosis may be possible by combining hsTn and clinical risk assessment, and by measuring short-term dynamic changes of hsTn (8–10,22). This may lead to further decreases in the numbers of patients requiring additional testing, including imaging. In addition, reduced need for coronary CTA imaging can be achieved in patients with hsTnI above the 99th percentile at the time of presentation who are at high risk for ACS.
However, the major diagnostic challenge is the large group of patients with intermediate levels of hsTn. In a recent study, these patients had non-negligible rates of ACS (8.3%) during the index hospitalization and also significantly higher rate of MI in the first 30 days after ED discharge versus patients with hsTn T below the LOD (3.08% vs. 0.17%) (23). Our results confirm these observations (ACS rate: 8.6%) and suggest that patients with intermediate hsTnI at the time of presentation require further evaluation and cannot be safely discharged home.
Serial measurements of hsTnI improved the detection and exclusion of ACS in previous studies (22,24). In our study, the addition of second and third hsTnI measurements at approximately 2 and 4 h after the presentations did not improve ACS risk classification. However, serial hsTn measurements were not available in all patients, potentially including bias to our observations. Further studies will be needed to explore whether serial hsTn measurements can help in the management of patients, especially in patients with CAD and intermediate stenosis on coronary CTA.
Incremental value of advanced coronary CTA assessment
We showed the incremental value of coronary CTA to accurately stratify patients with intermediate hsTnI who are at intermediate risk of ACS. We reclassified 71.9% of patients with intermediate hsTnI using coronary CTA and decreased the fraction of patients remaining at intermediate risk for ACS after both assessments from 43.8% to 24.4%. This also improved specificity for ACS from 48.2% to 68.1% as compared to traditional coronary CTA and was achieved because the presence of high-risk plaque and ≥50% stenosis carried a very high risk of ACS (9 of 13 patients) in the group with intermediate hsTnI. We showed that patients with nonobstructive CAD, but no high-risk plaque did not develop ACS and hence, the fraction of low-risk patients increased from 42.5% to 60.0%, while maintaining sensitivity and negative predictive values for ACS at 100%. These findings resulted in a significant improvement in the discriminatory ability for ACS (AUC: 0.74 to 0.84; p > 0.001).
The patients with intermediate hsTnI and either high-risk plaque or ≥50% stenosis remained at intermediate risk of ACS (n = 3 of 39). All 3 patients with ACS had high-risk plaque, but none had ≥50% stenosis. These findings are consistent with invasive angiographic studies showing a minority of patients (12% to 14%) who develop ACS in the absence of hemodynamically significant stenosis (25,26).
Implications for management of acute chest pain patients
Although this is an observational study, the results carry important implications for patient management. We found a small but important number of patients with hsTnI below the LOD at the time of ED might be rapidly triaged home without further testing. Further studies are warranted to determine whether the fraction of patients to be potentially immediately discharged without coronary CTA can be improved by including risk factors and clinical characteristics of chest pain and whether this fraction is stable across different hsTn assays. After coronary CTA, 60% of patients, including those with hsTnI below the LOD and those with intermediated hsTnI, but no ≥50% coronary stenosis and no high-risk plaque on coronary CTA, could be candidates for immediate discharge. Patients with hsTnI above the 99th percentile at the time of presentation are at high risk for ACS and appropriate guideline recommended therapies, such as dual antiplatelet therapy, high-dose statin, anticoagulation, and early invasive strategy could be considered without coronary CTA. Similar guideline-directed ACS therapies could be considered after coronary CTA shows both coronary stenosis and high-risk plaque in patients with intermediate hsTnI as they have a high risk of ACS. After the first hsTnI and early coronary CTA, approximately one-quarter of patients remain at intermediate risk for ACS for whom observation could be considered, including serial troponin measurements, aspirin, statin, and a stress test.
The measurements of hsTnI were available only in a subpopulation of patients in the ROMICAT II trial. This limited our sample size and could introduce a bias. However, the baseline characteristics of patients with hsTnI measurements were not significantly different from the entire population of patients in the coronary CTA arm of the ROMICAT II trial. We only used 1 hsTn assay. The LOD, sensitivity, and specificity of hsTn assays vary and thus could affect the performance of the test. Our results might not be generalizable to other hsTn assays. The strategy of hsTnI at the time of presentation with early coronary CTA was not pre-defined in the ROMICAT II trial and no actual ED disposition decisions were made based on these results. As such, our data should be interpreted with caution and are mostly hypothesis generating. The interpretation of coronary CTA images was performed in the setting of a core lab, by experienced readers, and with unlimited time for interpretation. Further prospective investigations will be required to determine whether clinical coronary CTA readers can reproduce the results and whether coronary CTA assessment of high-risk plaque features can be implemented into clinical workflow. Unstable angina pectoris is a clinical diagnosis supported by more objective evidence on advanced cardiac testing and remains a challenge for clinicians and in the setting of clinical trials. However, in the ROMICAT II trial, an independent clinical endpoints committee provided a rigorous high-quality adjudication of potential unstable angina pectoris according to pre-defined criteria.
Combined hsTnI at the time of presentation followed by early coronary CTA with the assessment for both stenosis and high-risk plaque improved the diagnostic accuracy for ACS as compared to conventional troponin and traditional assessment of coronary CTA. This has the potential to improve risk stratification of ED patients presenting with symptoms suggestive of ACS.
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: Our results provide new insights into the accuracy of a management strategy for patients presenting to the ED with suspected ACS. Combined hsTnI at the time of presentation followed by early coronary CTA with the assessment for both stenosis and high-risk plaque improved the diagnostic accuracy for ACS as compared to conventional troponin and traditional assessment of coronary CTA for stenosis. The education of referring providers will be critical to assure that the results of hsTn and advanced coronary CTA are appropriately interpreted and incorporated in the clinical decision making.
TRANSLATIONAL OUTLOOK: This was an observational study and no actual clinical decisions were made based on the results of hsTnI and advanced coronary CTA assessment. The use of combined hsTnI and advanced assessment of coronary CTA should be tested in a clinical trial in which clinical decisions and care will be guided by the test results.
The ROMICAT II trial is supported by the National Institutes of Health grant numbers NIH U01HL092040 and U01HL092022, ACRIN. The content of this paper is solely the responsibility of the authors and does not necessarily reflect the views of the National Institutes of Health or the Department of Health and Human Services. Dr. Ferencik has received a research grant from the American Heart Association Fellow to Faculty Award 13FTF16450001. Dr. Truong has received research grants from NIH/NHLBI K23HL098370 and L30HL093896, St. Jude Medical, American College of Radiology Imaging Network, and Duke Clinical Research. Dr. Peacock has received research grants from Abbott, Alere, Banyan, Cardiorentis, Portola, Roche, and The Medicines Company; has ownership of Comprehensive Research Associates LLC and Emergencies in Medicine LLC; is a consultant with and on advisory boards for BG Medicine, Beckman, Boehringer-Ingelheim, Instrument Labs, Prevencio, The Medicines Company, ZS Pharma, Alere, Cardiorentis, and Janssen. Dr. Nagurney has received research grants from Alere/Biosite, Brahms Ltd/Thermo-Fisher, Nanosphere; is a consultant for and on advisory board at CardioDx. Dr. Januzzi received research grants from Siemens, Thermo Fisher, and Singulex; is a consultant with and on advisory board of Critical Diagnostics, Sphingotec, and Roche. Dr. Hoffmann received research grants from NIH U01HL092040, U01HL092022, Siemens Medical Solutions, Heart Flow Inc.; and is a consultant for and on advisory board of Heart Flow. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Ferencik and Liu contributed equally to this work.
- Abbreviations and Acronyms
- acute coronary syndrome
- area under the receiver operating characteristics curve
- coronary artery disease
- confidence interval
- computed tomography angiography
- emergency department
- highly sensitive troponin
- Hounsfield units
- limit of detection
- negative predictive value
- positive predictive value
- Received April 6, 2015.
- Revision received June 4, 2015.
- Accepted June 4, 2015.
- American College of Cardiology Foundation
- Apple F.S.,
- Collinson P.O.
- Giannitsis E.,
- Kurz K.,
- Hallermayer K.,
- Jarausch J.,
- Jaffe A.S.,
- Katus H.A.
- Goldstein J.A.,
- Chinnaiyan K.M.,
- Abidov A.,
- et al.
- Body R.,
- Carley S.,
- McDowell G.,
- et al.
- Schlett C.L.,
- Truong Q.A.,
- Ahmed W.,
- et al.
- Puchner S.B.,
- Liu T.,
- Mayrhofer T.,
- et al.
- Ladapo J.A.,
- Jaffer F.A.,
- Hoffmann U.,
- et al.
- Hulten E.,
- Pickett C.,
- Bittencourt M.S.,
- et al.
- Wright R.S.,
- Anderson J.L.,
- Adams C.D.,
- et al.
- Bandstein N.,
- Ljung R.,
- Johansson M.,
- Holzmann M.J.
- Roe M.T.,
- Harrington R.A.,
- Prosper D.M.,
- et al.